Lilly price break reverses NICE’s 'No' ruling on breast cancer drug Verzenio

Last October, England’s drug-cost watchdogs dealt Eli Lilly a blow when they decreed that the company’s CDK 4/6 inhibitor to treat breast cancer, Verzenio, wasn’t cost-effective. So Lilly dished up a new price break—and now the National Institute for Health and Care Excellence (NICE) is on board. The problem, initially, was that Lilly couldn’t provide evidence that Verzenio… Read More »